Company research / GWLL
Goldenwell Biotech, Inc. (GWLL)
- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Goldenwell Biotech, Inc. reported revenue of $55. Revenue fell 60.4% from the prior annual period.
Key ratios (year ended 2025-12-31)
21.8%
Gross margin
n/m
Operating margin
n/m
Net margin
-60.4%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55 | n/a | n/a | n/a | $139 | n/a | n/a | n/a | $1.8K | n/a |
| Cost of Revenue | $43 | n/a | n/a | n/a | $75 | n/a | n/a | n/a | $1.2K | n/a |
| Gross Profit | $12 | n/a | n/a | n/a | $64 | n/a | n/a | n/a | $666 | n/a |
| Operating Income | -$113.3K | n/a | n/a | n/a | -$123.1K | n/a | n/a | n/a | -$115.8K | n/a |
| Net Income | -$296.5K | n/a | n/a | n/a | -$131.5K | n/a | n/a | n/a | -$117.4K | n/a |
| EPS (Diluted) | $0.00 | n/a | n/a | n/a | $0.00 | n/a | n/a | n/a | $0.00 | n/a |
| Total Assets | $36.1K | n/a | n/a | n/a | $224.2K | n/a | n/a | n/a | $228.1K | n/a |
| Total Liabilities | $379.8K | n/a | n/a | n/a | $271.4K | n/a | n/a | n/a | $143.8K | n/a |
| Shareholders' Equity | -$343.7K | -$144.0K | -$116.1K | -$85.8K | -$47.2K | -$20.9K | $3.4K | $53.3K | $84.3K | $105.5K |
| Operating Cash Flow | -$22.6K | n/a | n/a | n/a | -$123.1K | n/a | n/a | n/a | -$113.2K | n/a |
| Shares Outstanding | 99.00M | n/a | n/a | n/a | 99.00M | n/a | n/a | n/a | 99.00M | n/a |
| Weighted Average Diluted Shares | 99.00M | n/a | n/a | n/a | 99.00M | n/a | n/a | n/a | 99.00M | n/a |